Jump to content

Perindopril/indapamide: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{drugbox}} (no changed fields - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_
BogBot (talk | contribs)
Bots
53,132 edits
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Line 2: Line 2:
{{Drugbox
{{Drugbox
| verifiedrevid = 398782024
| verifiedrevid = 398782024

⚫
| type = combo
<!--Combo data-->
⚫
| component1 = Perindopril
⚫
| type = combo
| class1 = [[ACE inhibitor]]
⚫
| component1 = Perindopril
⚫
| component2 = Indapamide
| class2 = [[diuretic]]
| class1 = [[ACE inhibitor]]
⚫
| component2 = Indapamide
| class2 = [[diuretic]]

<!--Clinical data-->
| tradename =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category =
⚫
| legal_AU = S4
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status = Rx-only
⚫
| routes_of_administration = Oral

<!--Identifiers-->
⚫
| CAS_number =
⚫
| ATC_prefix = C09
⚫
| ATC_suffix = BA04
⚫
| PubChem = 9940214
⚫
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8115834
| ChemSpiderID = 8115834

<!--Chemical data-->
⚫
| smiles = O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@H]12)C)CCC.O=S(=O)(N)c1c(Cl)ccc(c1)C(=O)NN3c2ccccc2CC3C
| InChI = 1/C19H32N2O5.C16H16ClN3O3S/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h12-16,20H,4-11H2,1-3H3,(H,23,24);2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)/t12-,13-,14-,15-,16-;/m0./s1
| InChI = 1/C19H32N2O5.C16H16ClN3O3S/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h12-16,20H,4-11H2,1-3H3,(H,23,24);2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)/t12-,13-,14-,15-,16-;/m0./s1
| InChIKey = LRRJSCKXFJTRLC-MHXJNQAMBS
| InChIKey = LRRJSCKXFJTRLC-MHXJNQAMBS
⚫
| smiles = O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@H]12)C)CCC.O=S(=O)(N)c1c(Cl)ccc(c1)C(=O)NN3c2ccccc2CC3C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H32N2O5.C16H16ClN3O3S/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h12-16,20H,4-11H2,1-3H3,(H,23,24);2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)/t12-,13-,14-,15-,16-;/m0./s1
| StdInChI = 1S/C19H32N2O5.C16H16ClN3O3S/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h12-16,20H,4-11H2,1-3H3,(H,23,24);2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)/t12-,13-,14-,15-,16-;/m0./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LRRJSCKXFJTRLC-MHXJNQAMSA-N
| StdInChIKey = LRRJSCKXFJTRLC-MHXJNQAMSA-N
⚫
| CAS_number =
⚫
| ATC_prefix = C09
⚫
| ATC_suffix = BA04
⚫
| PubChem = 9940214
⚫
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫
| DrugBank =
⚫
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category=
⚫
| legal_AU = S4
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status = Rx-only
⚫
| routes_of_administration = Oral
}}
}}


Revision as of 06:46, 31 August 2011

Perindopril/indapamide
Combination of
PerindoprilACE inhibitor
Indapamidediuretic
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • In general: ℞ (Prescription only)
Identifiers
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
3D model (JSmol)
  • O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@H]12)C)CCC.O=S(=O)(N)c1c(Cl)ccc(c1)C(=O)NN3c2ccccc2CC3C
  • InChI=1S/C19H32N2O5.C16H16ClN3O3S/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h12-16,20H,4-11H2,1-3H3,(H,23,24);2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)/t12-,13-,14-,15-,16-;/m0./s1 checkY
  • Key:LRRJSCKXFJTRLC-MHXJNQAMSA-N checkY
  (verify)

Perindopril/indapamide is a combination therapy for the treatment of Essential hypertension.

Form and Composition

Each scored tablet contains 2 mg of perindopril tert-butylamine salt and 0.625 mg of indapamide.

Indication

Essential hypertension.

Dosage and Administration

One tablet daily, preferably to be taken in the morning and before a meal.

Pharmacological Action

PRETERAX, a fixed combination of an ACE inhibitor and a chlorosulfamoyl diuretic, leads to additive synergy of the antihypertensive effects of the two constituents. Its pharmacological properties are derived from those of each of the components taken separately, in addition to those due to the additive synergistic action of the two constituents, when combined, on vascular endothelium, arteriolocapillary microcirculation, and the target organs of hypertension. Elderly patients: Normal dosage. Renal failure: Creatinine clearance (CrCl) >30 mL/min: no dosage modification. CrCl <30 ml/min: treatment contraindicated.

Contraindications

Absolute: Known allergy to perindopril, indapamide, or sulfonamides; history of Quincke's edema linked to previous ACE inhibitor therapy; severe renal failure; serious liver disorder; hyperkalemia; pregnancy; lactation. Relative: Combination therapy with lithium, potassium salts, potassium-sparing diuretics, and certain medicines which can cause heart rhythm disorders.

Side Effects

Asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur.

Warnings

Immunosuppressed patients. Hemodialysis: risk of anaphylactoid reaction during hemodialysis with polyacrylonitrile membranes. Liver impairment.

Precautions

Disorders of electrolyte balance, diabetes, gout, hypotension, or strict sodium-free diets, heart or renal failure, atherosclerosis, renal artery stenosis, elderly.

Drug Interactions

Not recommended: Combinations with lithium, potassium-sparing diuretics, potassium (salts), antiarrhythmic drugs which cause torsade de pointes, anesthetic drugs, cytostatic or immunosuppressive agents.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Perindopril/indapamide&oldid=447615092"